PR97729

SYDNEY, Sept. 9, 2022 /PRNewswire=KYODO JBN/ --

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug

development company, today announced that final data from its phase II study of

paxalisib in patients with newly diagnosed glioblastoma will be the subject of

an oral presentation at the upcoming annual congress of the European Society

for Medical Oncology (ESMO), which will be held in person from 9-13 September

2022 in Paris, France.

The oral presentation will summarise key findings of the completed phase II

study of paxalisib in glioblastoma, which was previously the subject of a

poster presentation at the American Society for Clinical Oncology (ASCO) Annual

Meeting in Chicago, IL, in June 2022. The presentation will provide additional

detail on pharmacokinetics and pharmacodynamics. The presentation will be

delivered by Professor John de Groot, Division Chief of Neuro-Oncology at the

University of California, San Francisco, one of the principal investigators on

the study.

ORAL PRESENTATION

Title: Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed

glioblastoma patients with unmethylated MGMT promoter status: Final phase II

study results.

Date: Friday, 9 September

Session: CNS Tumours

Abstract ID: 2800

For More Information, Please Contact:-

In the United States:

Joe Green

Edison Investor Relations

jgreen@edisongroup.com

Phone: +1 646-653-7030

In Australia:

Jane Lowe

IR Department

jane.lowe@irdepartment.com.au

Phone: +61 411 117 774

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug

development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt /

mTOR pathway, which is being developed to treat glioblastoma, the most common

and most aggressive form of primary brain cancer in adults. Licensed from

Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal

study in glioblastoma, in January 2021. Seven additional studies are active in

various forms of brain cancer. Paxalisib was granted Orphan Drug Designation

for glioblastoma by the US FDA in February 2018, and Fast Track Designation for

glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted

Rare Pediatric Disease Designation and Orphan Designation by the US FDA for

DIPG in August 2020, and for AT/RT in June 2022.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which

was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to

be active against a broad range of tumour types and has provided compelling

evidence of synergy with immuno-oncology agents. A phase I study commenced

recruitment in November 2021.

For more information, please visit www.kaziatherapeutics.com or follow us on

Twitter @KaziaTx.

This document was authorized for release to the ASX by James Garner, Chief

Executive Officer, Managing Director.

SOURCE  Kazia Therapeutics Limited